What is CorMedix?
CorMedix Inc., formerly Picton Holding Company, Inc., is a biopharmaceutical entity headquartered in Berkeley Heights, New Jersey. Established in 2006, the company is dedicated to the development and commercialization of innovative therapeutic products aimed at combating infectious and inflammatory diseases within the United States. Its primary focus is on DefenCath, an antimicrobial catheter lock solution designed to mitigate the occurrence of catheter-related bloodstream infections in patients undergoing kidney failure treatment.
How much funding has CorMedix raised?
CorMedix has raised a total of $12.5M across 1 funding round:
Stock Offering
$12.5M
Stock Issuance/Offering (2010): $12.5M, investors not publicly disclosed
What's next for CorMedix?
The substantial enterprise-level funding CorMedix has attracted, particularly the recent strategic investment, signals a strong confidence in its product development and market strategy. This capital infusion is expected to accelerate the advancement of DefenCath through clinical trials and regulatory processes, positioning CorMedix for potential market entry and commercialization. The company's focus on addressing critical unmet needs in infection prevention, especially within the dialysis patient population, suggests a clear path for growth and impact in the biopharmaceutical sector.
See full CorMedix company page
